Ajanta Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Ajanta Pharma Ltd. on BSE

Load latest

Ajanta Pharma Ltd.

23 Feb 2022

2542.60

0.13%

SAST

AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 23, 2022 for Ravi Agrawal, trustee Ravi Agrawal Trust

Ajanta Pharma Ltd.

21 Feb 2022

2542.60

0.13%

SAST

AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 21, 2022 for Ravi Agrawal, trustee Ravi Agrawal Trust

pdf

Ajanta Pharma Ltd.

04 Feb 2022

2542.60

0.13%

Earnings Call

AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Further to our communication dated 31st January 2022 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 31st January 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link: http://www.ajantapharma.com/AdminData/Results/EarningsCallTranscriptQ3(Oct-Dec)2021-22.pdf This is for your information and records please.

pdf

Ajanta Pharma Ltd.

01 Feb 2022

2542.60

0.13%

Company Update

AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copies of financial results of the Company for the quarter and nine months ended 31st December 2021 published in the following newspapers on 1st February 2022: 1. Mumbai edition of Economic Times and 2. Mumbai edition of Maharashtra Times This is for your information and record.

pdf

Ajanta Pharma Ltd.

01 Feb 2022

2542.60

0.13%

Earnings Call for Q3FY22 of Ajanta Pharma

Conference Call with Ajanta Pharma Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.

audio

Ajanta Pharma Ltd.

31 Jan 2022

2542.60

0.13%

Earnings Call

AJANTA PHARMA LTD. - 532331 - Audio Recording Of Earnings Call Conducted On 31St January 2022

BSE India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 31st January 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link: http://www.ajantapharma.com/AdminData/Results/EarningsCallAudioQ3(Oct-Dec)2021-22.mp3

pdf

Ajanta Pharma Ltd.

31 Jan 2022

2542.60

0.13%

Board Meeting

AJANTA PHARMA LTD. - 532331 - Board Meeting Outcome for Outcome Of Board Meeting

BSE India

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following: i. Press Release being issued on the Results for the quarter and nine months ended 31st December 2021; ii. Unaudited Consolidated Financial Results for the quarter and nine months ended 31st December 2021; iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the quarter and nine months ended 31st December 2021; iv. Unaudited Standalone Financial Results for the quarter and nine months ended 31st December 2021; v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the quarter and nine months ended 31st December 2021; vi. Investors' presentation. Kindly note that the meeting of the Board of Directors commenced at 1.45 p.m. and concluded at 3.15 p.m. and take the above on your records.

pdf

Ajanta Pharma Ltd.

27 Jan 2022

2542.60

0.13%

Company Update

AJANTA PHARMA LTD. - 532331 - Schedule Of Earnings Conference Call Post Board Meeting

BSE India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 31st January 2022, post Board meeting. This is for your information and records please.

pdf

Ajanta Pharma Ltd.

21 Jan 2022, 04:09PM

2542.60

0.13%

Board Meeting

AJANTA PHARMA LTD. - 532331 - Board Meeting Intimation for Board Meeting Intimation For Quarterly Results

BSE India

AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2022 ,inter alia, to consider and approve We hereby inform that a Meeting of the Board of Directors of the Company will be held on Monday, 31st January 2022 to inter-alia consider and approve unaudited consolidated & standalone financial results of the Company for the third quarter ended 31st December 2021. You are requested to please take a note of the same and disseminate to all concerned.

pdf

Ajanta Pharma Ltd.

21 Jan 2022

2542.60

0.13%

Company Update

AJANTA PHARMA LTD. - 532331 - Letter Of Offer For Buy-Back Of Shares

BSE India

This is in regards to the captioned Buyback and is further to our letter dated 5th January 2022 whereby we had submitted the Draft Letter of Offer. The Company is undertaking the Buyback in accordance with the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended (the 'Buyback Regulations') and the Companies Act, 2013, as amended. Please find enclosed the soft copy (in pdf version) of the letter of offer dated 19th January 2022 of the Company in relation to the Buyback Offer ('Letter of Offer') for your information and records. The Buy-back offer will open on Thursday, February 03, 2022 and will close on Wednesday, February 16, 2022. All terms used herein and not specifically defined shall have the same meaning as ascribed to such terms under the Letter of Offer.

pdf

Is Ajanta Pharma Ltd. worth buying?

189 Votes:

Buy 77.25%

Sell 15.87%

Hold 6.88%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf